In February 2019, we engaged with Takeda Pharmaceutical Company Ltd, a global pharmaceutical company that focuses on 5 key therapy areas. (See photo)
Neurological disorders is one of their key therapy areas and we were pleased to be approached to assist with conducting research in narcolepsy which is a new disease area for Takeda.
Our Chair, Matt O’Neill, has been working closely with Takeda since then, as we do with many of the lead pharmaceutical companies in the narcolepsy field. In Zurich this week, Matt took part in a Narcolepsy Advisory Board to enhance understanding of narcolepsy from the patient perspective.
This is a great example of our early engagement, based on our reputation as a leading patient organisation in this field and our commitment to raising awareness across all aspects of life.
You can find a link to Takeda’s latest public announcements on progress with research into Narcolepsy here.
Photo courtesy of Takeda Pharmaceutical Company Ltd
Individuals from left to right feature: Peter Wheatley Price (Market Access & Pricing Director UK & Ireland), Andy Boateng (Evidence Generation Manager, HTA Centre of Excellence), Matt O’Neill, Chair, Narcolepsy UK, Cressida Ward (Communications & Patient Advocacy Director UK & Ireland), Gemma Kay (Evidence Generation Manager HTA Centre of Excellence), Jon Neal (Managing Director, Takeda UK & Ireland).
